About: An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon
Creator	Zhu, Jie Deng, Yong-Qiang Qin, Cheng-Feng Wang, Xin Li, Xiao-Feng Zhang, Bowen Zhang, Na-Na Liu, Zurui Xie, Zhengwei
Source	BioRxiv
abstract	The pandemic COVID-19 has spread to all over the world and greatly threatens safety and health of people. COVID-19 is highly infectious and with high mortality rate. As no effective antiviral treatment is currently available, new drugs are urgently needed. We employed transcriptional analysis to uncover potential antiviral drugs from natural products or FDA approved drugs. We found liquiritin significantly inhibit replication of SARS-CoV-2 in Vero E6 cells with EC50 = 2.39 μM. Mechanistically, we found liquiritin exerts anti-viral function by mimicking type I interferon. Upregulated genes induced by liquiritin are enriched in GO categories including type I interferon signaling pathway, negative regulation of viral genome replication and etc. In toxicity experiment, no death was observed when treated at dose of 300 mg/kg for a week in ICR mice. All the organ indexes but liver and serum biochemical indexes were normal after treatment. Liquiritin is abundant in licorice tablet (~0.2% by mass), a traditional Chinese medicine. Together, we recommend liquiritin as a competitive candidate for treating COVID-19. We also expect liquiritin to have a broad and potent antiviral function to other viral pathogens, like HBV, HIV and etc.
has issue date	2020-05-02(xsd:dateTime)
bibo:doi	10.1101/2020.05.02.074021
has license	biorxiv
sha1sum (hex)	120d8445f90ba5e9aa998a2dd1665a41cd330624
schema:url	https://doi.org/10.1101/2020.05.02.074021
resource representing a document's title	An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon
schema:publication	bioRxiv
resource representing a document's body	covid:120d8445f90ba5e9aa998a2dd1665a41cd330624#body_text
is schema:about of	named entity 'antiviral drugs' named entity 'liquiritin' named entity 'Vero E6' named entity 'biochemical' named entity 'licorice' named entity 'COVID-19' named entity 'COVID-19' named entity 'viral pathogens' named entity 'FDA' named entity 'ICR mice' named entity 'incubation' named entity 'Vero E6' named entity 'lung' named entity 'adrenal gland' named entity 'cytotoxic' named entity 'Type I interferon' named entity 'viral replication' named entity 'EGFR' named entity 'TRIM27' named entity 'anti-inflammatory effect' named entity 'MTT assay' named entity 'micromolar concentration' named entity 'gene expression' named entity 'CHMP5' named entity 'IL13' named entity 'Vero Cell' named entity 'anti-viral drug' named entity 'Vero E6' named entity 'gene' named entity 'COVID-19' named entity '293T cells' named entity 'antidepressant' named entity 'necropsy' named entity 'gene' named entity 'ISGs' named entity 'qRT-PCR' named entity 'SARS-CoV-2' named entity 'infection' named entity 'IFIT1' named entity 'INFs' named entity 'MCF7' named entity 'DAG1' named entity 'CXADR' named entity 'dose-response curve' named entity 'biomolecule' named entity 'Vero cells' named entity 'Supp' named entity 'tetratricopeptide repeats' named entity 'tissue culture infectious dose' named entity 'absorbance' named entity 'APOBEC1' named entity 'liquiritin' named entity 'complex systems' named entity 'antiviral' named entity 'viral replication' named entity 'liquiritin' named entity 'animal test' named entity 'cholesterol' named entity 'myocardial ischemia' named entity 'antiviral activity' named entity 'p-value' named entity 'SARS-CoV-2' named entity 'biosafety level 3' named entity 'inhalation' named entity 'procaterol' named entity 'liquiritin' named entity 'p-value' named entity 'low-density lipoprotein' named entity 'liquiritin' named entity 'liquiritin' named entity 'ICAM1' named entity 'virus' named entity '0.21' named entity 'glucose' named entity 'Liquiritin' named entity 'Gene Expression Omnibus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software